Teva Pharmaceutical has announced positive topline results from an ongoing Phase IIa study of TEV ‘408, an investigational anti-interleukin-15 monoclonal antibody, in adults with coeliac disease.  

The study met its primary endpoint, demonstrating statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week eight. TEV ‘408 was well-tolerated, with no safety signals observed to date. 

“A strict gluten-free diet has long been the only option for people living with coeliac disease. Yet, even with strict adherence to a gluten-free diet, many continue to experience symptoms, intestinal damage and a significant impact on their daily lives,” said Dr Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer at Teva.  

“These results underscore the potential to move beyond managing gluten exposure and address coeliac disease at its biological source. They also strengthen our confidence in targeting the IL-15 pathway as an approach to reducing immune-driven intestinal damage.” 

The ongoing randomised, placebo-controlled study enrolled 50 adult participants with coeliac disease on a gluten-free diet (GFD) with minimal intestinal damage at baseline as measured by the villous height-to-crypt depth ratio (Vh:Cd ≥2.0) and symptoms.  

Two weeks after receiving a single dose of TEV ‘408, participants began a six-week daily gluten challenge (GC). The study assessed biopsy-based measures of intestinal damage and inflammation along with patient-reported symptoms. At week eight (the end of the GC) TEV ‘408: 

  • Showed statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo 
  • Showed a favourable effect on intestinal inflammation as measured by density of intraepithelial lymphocytes (IELs) compared with placebo 
  • Demonstrated lower GI symptom scores versus placebo 

TEV ‘408 is designed to inhibit interleukin-15 (IL-15), a cytokine involved in immune-mediated pathways.